Market News & Trends
MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza in Pediatric Population
MannKind Corporation recently announced the enrollment of the first pediatric patient in the INHALE-1 study. The multi-center study will evaluate the efficacy and safety of….
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
InMed Pharmaceuticals Inc. recently announced it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time….
Avacta Group Announces Achievement of Preclinical Development Milestone in LG Chem Life Sciences Partnership
Avacta Group plc recently announced a preclinical development milestone has been achieved in the multi-target therapeutics development partnership with LG Chem Life Sciences, the life sciences division of the South Korean LG Group, triggering an….
Boehringer Ingelheim & OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in Combination With Anti-PD-1 Antibody Ezabenlimab, in Patients With Advanced Endometrium or Colorectal Tumors
Boehringer Ingelheim and OSE Immunotherapeutics SA recently announced that the first patient has been dosed in the expansion phase of the Phase 1 clinical trial…
Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders Through Research Collaboration With Mayo Clinic
Castle Creek Biosciences, Inc. recently announced a research collaboration with Mayo Clinic to advance discovery and preclinical development of investigational gene therapy candidates for the…
Adaptive Biotechnologies Launches Enhanced clonoSEQ Assay Reports for Patients With Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status
Adaptive Biotechnologies Corporation recently announced the launch of an enhanced version of its clonoSEQ B-cell Clonality (ID) report, which will now feature the immunoglobulin heavy…
Starton Therapeutics Announces Successful Results in STAR-LLD Toxicology Study: No Myelosuppression & Excellent Tolerability
Starton Therapeutics Inc. recently announced the results of a preclinical toxicology study for STAR-LLD. STAR-LLD is a continuous delivery system of lenalidomide in development for…
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, & Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
Minerva Neurosciences, Inc. recently announced results from a pivotal bioequivalence study comparing the roluperidone formulations used in its late-stage Phase 2b and Phase 3 trials,…
Catalent Opens New Full-Service Clinical Supply Facility in Shiga, Japan
Catalent recently announced the opening of its new clinical supply facility, strategically located in the Shiga prefecture of Japan, in response to increased demand for…
Croda Donates 1,000 Solar Panel Modules to Non-Profit Organizations
Croda International Plc, the name behind high-performance ingredients and technologies that are relied on by industries and consumers everywhere, has donated 1,000 SunPower solar panels…
Novigenix & Radbound University Medical Center Discover the First Blood-Based ImmunoTranscriptomic Biomarkers for Response to Anti-PD-1 Therapy
Novigenix SA recently announced release of the article Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. Immune checkpoint inhibitors (ICIs) have become….
Genetron Health & IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline
Genetron Holdings Limited recently announced a partnership with IMPACT Therapeutics in which the two parties will cooperate together on research and development for synthetic lethal inhibitors that are based on….
Evelo Biosciences Announces Positive Phase 2 Clinical Data With EDP1815 in Psoriasis
Evelo Biosciences, Inc. recently announced positive data from its Phase 2 study evaluating EDP1815 versus placebo for the treatment of mild and moderate psoriasis. A statistically significant reduction in the….
Salarius Pharmaceuticals Receives $2.7 Million in Payment From the Cancer Prevention & Research Institute of Texas
Salarius Pharmaceuticals, Inc. recently announced the receipt of a $2.7-million payment under its existing contract with the Cancer Prevention and Research Institute of Texas (CPRIT).…
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar & Vaginal Atrophy
Daré Bioscience, Inc. recently announced the initiation of a Phase 1/2 clinical study of DARE-VVA1, a novel intravaginal tamoxifen product being developed for the treatment…
Soligenix Announces Accelerated Publication Demonstrating Efficacy & Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
Soligenix, Inc. recently announced publication of preclinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program) demonstrating durable broad-spectrum neutralizing antibody responses, including against the…
First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients With Ulcerative Proctitis & Ulcerative Proctosigmoiditis
First Wave BioPharma, Inc. recently announced it has begun screening patients for enrollment in a Phase 2b clinical trial investigating a topical formulation of FW-UP…
New BD Cell Analyzer Includes Spectral Analysis Capabilities
BD (Becton, Dickinson and Company) recently announced the launch of a spectral-enabled cell analyzer, expanding current cell analyzer capabilities to at least 34 parameters with…
BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery & Development & Advances in Neuroscience Portfolio
BioXcel Therapeutics, Inc. recently hosted a virtual R&D Day that discussed new applications of the artificial intelligence ecosystem to augment and accelerate its drug candidate…
ESCP Models - Hepatitis C Medications (Part 1)
In a series of four articles earlier this year, the principles of the ESCP Analysis process were outlined with a few simple to understand examples. To better explain the application of the process, I have summarized the evolution of Hepatitis C (HCV) treatment from naked Interferon alpha treatment through to the latest….
